TORONTO -- An investigational anti-fibrotic agent is showing promise in the treatment of idiopathic pulmonary fibrosis (IPF), a researcher said here.
ATS: Pirfenidone Slows IPF Lung DeclinesCourtesy MedPage Today Allergy & Immunology Tue, 05/20/2008 - 14:05
TORONTO -- An investigational anti-fibrotic agent is showing promise in the treatment of idiopathic pulmonary fibrosis (IPF), a researcher said here. Popular products More related itemsNanotechnology may increase longevity of dental...
Strep B Screening Guidelines Quickly Adopted (CME/CE)
Wii-hab may enhance Parkinson's treatment
|
Popular by tags WeekMonth |
Post new comment